Brief Report: A Phase IIb Trial of a Novel Extended‐Release Microsphere Formulation of Triamcinolone Acetonide for Intraarticular Injection in Knee Osteoarthritis by Conaghan, PG et al.
BRIEF REPORT
A Phase IIb Trial of a Novel Extended-Release Microsphere Formulation of
Triamcinolone Acetonide for Intraarticular Injection in Knee Osteoarthritis
Philip G. Conaghan,1 Stanley B. Cohen,2 Francis Berenbaum,3 Joelle Lufkin,4 James R. Johnson,4 and Neil Bodick4
Objective. FX006 is a novel, microsphere-based,
extended-release formulation of triamcinolone ace-
tonide for intraarticular (IA) injection designed to
maintain treatment concentration in the joint and pro-
vide prolonged analgesic benefits in patients with
osteoarthritis (OA) of the knee. This study was under-
taken to compare the analgesic benefits of 2 FX006
doses with saline placebo injection.
Methods. In this phase IIb study, participants
with knee OA (Kellgren/Lawrence grade 2–3) and aver-
age daily pain (ADP) intensity ≥5 to ≤9 (on a 0–10
Numerical Rating Scale) were randomized (1:1:1) to
receive single IA injections of FX006 32 mg (n = 104) or
16 mg (n = 102) or saline placebo (n = 100). The primary
end point was the least squares mean (LSM) change
from baseline to week 12 in weekly mean ADP intensity
scores for FX006 32 mg versus saline placebo.
Results. The primary end point was not met (LSM
change at week 12 3.1 with FX006 32 mg versus 2.5
with saline placebo; LSM difference [95% confidence
interval] 0.58 [1.22, 0.07]) (P = 0.08). However,
improvements in ADP intensity were significantly greater
with FX006 32 mg than saline placebo at weeks 1–11 and
week 13. Improvements in ADP intensity were signifi-
cantly greater with FX006 16 mg versus saline placebo at
weeks 1–9. A dose-response effect in duration of maximal
analgesic effect was evident (13 weeks with 32 mg versus 9
weeks with 16 mg), with FX006 32 mg providing increased
therapeutic benefit relative to FX006 16 mg. All treat-
ments were well tolerated.
Conclusion. Although the primary end point was
not met, our findings indicate a prolonged reduction in
symptoms with FX006 with an evident dose response
and a safety profile similar to saline placebo.
Osteoarthritis (OA) of the knee is characterized by
pain, progressive cartilage destruction, subchondral bone
changes, and joint inflammation (1). Treatment guidelines
recommend intraarticular (IA) corticosteroids (2). Stan-
dard IA corticosteroids provide moderate improvements in
pain, but the magnitude of benefit rapidly wanes after
injection (3). FX006, an extended-release formulation of
triamcinolone acetonide in 75:25 poly(lactic-co-glycolic
acid) microspheres, was designed to maintain prolonged
concentrations of triamcinolone acetonide in the joint, with
the intent to improve analgesic effect and reduce systemic
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Figure 1. Disposition of the patients.
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exposure versus commercially available triamcinolone ace-
tonide crystalline suspension. In a pharmacokinetic study
(ClinicalTrials.gov identifier: NCT02637323), FX006 dem-
onstrated prolonged residency in synovial fluid and reduced
systemic exposure following IA injection versus triamcino-
lone acetonide crystalline suspension in people with knee
OA (4).
In the first clinical study of efficacy following a sin-
gle IA injection of FX006 (target low, mid, and high doses
of 10 mg, 40 mg, and 60 mg, respectively) in patients with
knee OA (ClinicalTrials.gov identifier: NCT01487161)
(5), the mid dose of FX006 yielded pain relief superior to
triamcinolone acetonide crystalline suspension 40 mg with
treatment differences achieving statistical significance at
weeks 5–10 (all P < 0.05) and numerical improvement at
each of weeks 2–12. Pain relief with the high dose of
FX006 compared with triamcinolone acetonide crystalline
suspension was similar to that for the mid dose through
week 6, but diminished from weeks 7 to 12. Pain relief was
numerically improved with the low dose of FX006 com-
pared with triamcinolone acetonide crystalline suspension
at each of weeks 2–12, but the effect did not achieve
statistical significance. Hence, the mid dose of FX006 was
concluded to be the most efficacious tested in that trial
(5) and further evaluation was deemed appropriate.
The present study (ClinicalTrials.gov identifier:
NCT02116972) was conducted to confirm the appropriate
target dose of FX006 and further assess FX006 efficacy
and safety. Two notable differences exist between the pre-
vious dose-ranging study (5) and the present one with
regard to administration and dosing of FX006. First, the
injection volume increased from 3 ml in the previous study
to 5 ml in the present study following adjustment of the
diluent volume to enhance microsphere dispersion and
reduce aggregation. Second, the FX006 doses reported
here (16 mg and 32 mg) reflect the amount of drug
received by patients following an ~20% reduction during
reconstitution, as determined by dose-delivery studies.
PATIENTS AND METHODS
In this phase IIb, double-blind, parallel-group, dose-rang-
ing, single-injection study, participants were randomized (1:1:1,
block of 6; by a centralized interactive web randomization system)
to receive a single 5-ml IA injection of FX006 16 mg, FX006 32
Table 1. Baseline demographic and disease characteristics of the patients with OA (full analysis set)*
FX006 16 mg
(n = 102)
FX006 32 mg
(n = 104)
Saline placebo
(n = 100)
Total
(n = 306)
Male, no. (%) 40 (39.2) 53 (51.0) 39 (39.0) 132 (43.1)
White, no. (%) 81 (79.4) 85 (81.7) 82 (82.0) 248 (81.0)
Age at consent, mean  SD years 58.2  8.34 58.7  8.06 59.7  8.23 58.8  8.20
BMI, mean  SD kg/m2 30.6  4.86 31.0  4.55 31.2  5.11 30.9  4.84
Weight category, no. (%)
Underweight (BMI <18.5) 2 (2.0) 0 (0.0) 0 (0.0) 2 (0.7)
Normal weight (BMI 18.5–24.9) 12 (11.8) 10 (9.6) 10 (10.0) 32 (10.5)
Overweight (BMI 25.0–29.9) 32 (31.4) 35 (33.7) 33 (33.0) 100 (32.7)
Obesity class I (BMI 30.0–34.9) 37 (36.3) 39 (37.5) 29 (29.0) 105 (34.3)
Obesity class II (BMI 35.0–39.9) 19 (18.6) 18 (17.3) 27 (27.0) 64 (20.9)
Morbid obesity (BMI ≥40.0) 0 (0.0) 2 (1.9) 1 (1.0) 3 (1.0)
Type of knee OA, no. (%)
Unilateral 45 (44.1) 46 (44.2) 38 (38.0) 129 (42.2)
Bilateral 57 (55.9) 58 (55.8) 62 (62.0) 177 (57.8)
Years since diagnosis, mean  SD 6.7  6.66 7.2  7.27 6.4  5.79 6.8  6.60
Kellgren/Lawrence grade, no. (%)
2 33 (32.4) 28 (26.9) 37 (37.0) 98 (32.0)
3 69 (67.6) 76 (73.1) 63 (63.0) 208 (68.0)
Prior index knee surgeries/interventions, no. (%)
Surgery or procedure 20 (19.6) 17 (16.3) 15 (15.0) 52 (17.0)
IA steroid injection 32 (31.4) 35 (33.7) 24 (24.0) 91 (29.7)
IA hyaluronic acid injection 6 (5.9) 11 (10.6) 19 (19.0) 36 (11.8)
ADP intensity, mean  SD
(0–10 scale)
6.6  0.97 6.5  1.01 6.7  1.08 6.6  1.02
WOMAC pain subscale, mean  SD
(0–4 scale)
2.3  0.62 2.1  0.58 2.3  0.65 2.2  0.62
WOMAC stiffness subscale, mean  SD
(0–4 scale)
2.5  0.74 2.4  0.71 2.4  0.68 2.4  0.71
WOMAC physical function subscale, mean  SD
(0–4 scale)
2.3  0.68 2.1  0.57 2.3  0.65 2.2  0.63
* The Patient Global Impression of Change (PGIC) is the patient’s report of change since baseline; thus, there is no
PGIC assessment at baseline. OA = osteoarthritis; BMI = body mass index; IA = intraarticular; ADP = average daily pain;
WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.
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Figure 2. A, Least squares mean (LSM) change from baseline (BL) in weekly mean average daily pain (ADP) intensity scores at the primary end
point at week 12 and key secondary end points at weeks 16, 20, and 24 (observed data; mixed model for repeated measures). B, Sensitivity analysis
of ADP intensity (imputed data; last observation carried forward/baseline observation carried forward). C, Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC) pain subscale. D, WOMAC physical function subscale (key secondary end point at week 12). E, Patient
Global Impression of Change score (key secondary end point at week 12) through week 24. FAS = full analysis set. Values are the LSM  SEM.
* = P < 0.05.
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mg, or saline placebo. Participants and assessors were blinded with
regard to treatment administered by a nonblinded injector. Details
related to randomization, blinding, and the injection procedure
are provided in the Supplementary text, available on the Arthritis
& Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.40364/abstract. After screening, participants were seen on
day 1 (baseline) and at weeks 4, 8, 12, 16, 20, and 24.
Eligible participants (ages ≥40 years, body mass index ≤40
kg/m2) had knee OA according to the American College of
Rheumatology clinical and radiologic criteria (6) for ≥6 months
before screening, a Kellgren/Lawrence grade of 2 or 3 on a cen-
trally read screening radiograph (7), pain in the index knee (de-
fined as the most painful knee in participants with bilateral
disease) on >15 days of the previous month, and a mean average
daily pain (ADP) intensity score ≥5 and ≤9 (on an 11-point
Numerical Rating Scale [NRS]). Patients were excluded if they
had ipsilateral hip OA, other arthritic/immune-mediated inflam-
matory disorders, or unstable knee joints (e.g., torn anterior cruci-
ate ligament) within 12 months of screening or received prior IA
corticosteroids within 3 months of screening, prior IA hyaluronic
acid injections in the index knee within 6 months of screening,
prior FX006 at any time, or intramuscular, oral, inhaled, intrana-
sal, or topical corticosteroids within 2 weeks of screening.
From screening through week 24, participants logged
daily ADP intensity scores via an interactive voice response
system, using a 0–10 NRS (where 0 = “no pain” and 10 =
“pain as bad as you can imagine”). Participants completed the
Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC) (8) on day 1 prior to randomization and at
weeks 4, 8, 12, 16, 20, and 24, and the Patient Global Impres-
sion of Change (PGIC) (9) at weeks 4, 8, 12, 16, 20, and 24.
Safety was evaluated via adverse events (AEs) sponta-
neously reported or discovered by the investigator from infor-
mation obtained via patient electronic diaries, routine
physical/laboratory evaluations, and assessments of the index
knee by an investigator who was blinded with regard to treat-
ment group. After informed consent was obtained, and for ≥7
days pretreatment, analgesic medications for index knee pain
Table 2. Summary of AEs among all treated patients*
FX006
16 mg
(n = 102)
FX006
32 mg
(n = 104)
Saline placebo
(n = 100)
Patients with ≥1 AE 43 (42.2) 46 (44.2) 43 (43.0)
AEs occurring in >2.0% of patients in any treatment group†
Arthralgia (any joint) 10 (9.8) 8 (7.7) 16 (16.0)
Back pain 3 (2.9) 2 (1.9) 2 (2.0)
Bronchitis 3 (2.9) 2 (1.9) 2 (2.0)
Headache 3 (2.9) 4 (3.8) 2 (2.0)
Joint swelling 4 (3.9) 5 (4.8) 5 (5.0)
Ligament sprain 4 (3.9) 4 (3.8) 2 (2.0)
Nasopharyngitis 2 (2.0) 2 (1.9) 4 (4.0)
Neck pain 0 (0.0) 3 (2.9) 0 (0.0)
Sinusitis 3 (2.9) 2 (1.9) 1 (1.0)
Toothache 0 (0.0) 3 (2.9) 1 (1.0)
Patients with ≥1 serious AE 1 (1.0) 3 (2.9) 0 (0.0)
Patients with ≥1 AE leading to study discontinuation 4 (3.9)‡ 4 (3.8)§ 1 (1.0)¶
Drug-related 1 (1.0)# 0 (0.0) 1 (1.0)#
Due to serious AE 0 (0.0) 1 (1.0)** 0 (0.0)
Patients with ≥1 index knee–related AE 15 (14.7) 14 (13.5) 17 (17.0)
Index knee–related AEs occurring in >2.0% of patients in
any treatment group†
Arthralgia 8 (7.8) 7 (6.7) 14 (14.0)
Joint swelling 4 (3.9) 4 (3.8) 3 (3.0)
Ligament sprain 3 (2.9) 1 (1.0) 0 (0.0)
Patients with ≥1 index knee–related serious AE 1 (1.0) 1 (1.0) 0 (0.0)
Patients with ≥1 index knee–related AE leading to
study discontinuation
4 (3.9)‡ 3 (2.9)§ 1 (1.0)¶
Drug-related 1 (1.0)# 0 (0.0) 1 (1.0)#
Due to serious AE 0 (0.0) 0 (0.0) 0 (0.0)
* Values are the number (%).
† Listed in alphabetical order.
‡ Joint effusion (day 131, grade 1, not related to study drug), arthralgia (day 57, grade 2, definitely related to
study drug), and joint swelling (day 57, grade 3, not related to study drug) in 1 patient each, and arthralgia,
arthritis, joint swelling, and synovial cyst all in 1 patient (day 88, all grade 2 and either not related or unlikely
related to study drug). All adverse events (AEs) were index knee related.
§ Joint swelling (day 84, grade 1, not related to study drug), worsening ankle osteoarthritis (OA) (day 37, grade
2, not related to study drug, serious), positive Klebsiella test (day 21, subsequently considered to be a false-posi-
tive finding by the investigator, grade 3, not related to study drug), and synovitis (day 112, grade 3, unlikely
related to study drug). All AEs were index knee related except ankle OA.
¶ Arthralgia (day 41, grade 3, probably related to study drug); index knee related.
# Arthralgia.
** Ankle OA.
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were not to be taken or used during the study with the excep-
tion of study-issued acetaminophen (≤3,000 mg/day in spon-
sor-provided 500-mg tablets) as rescue pain treatment.
The primary efficacy end point, change from baseline to
week 12 in weekly mean ADP intensity scores for FX006 32 mg
versus saline placebo in the full analysis set (all randomized and
treated participants), was analyzed using longitudinal mixed
model for repeated measures (MMRM) methodology on
observed data with no imputation for missing data (see the
Supplementary text, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40364/
abstract). A sample size of ~300 participants (100 per treatment
arm) was estimated to provide 80% power (2-sided alpha level
of 0.05) if the true underlying primary end point treatment effect
was 1.0 on the 0–10 NRS.
All secondary efficacy end points were first compared
between FX006 32 mg and saline placebo, followed by FX006 16
mg versus saline placebo. Predefined key secondary end points
(in order of step-down testing) were change from baseline to
week 12 in WOMAC physical function and PGIC scores, and
changes in weekly mean ADP intensity scores from baseline to
weeks 16, 20, and 24. Additional secondary outcomes included
percent of responders according to Outcome Measures in Rheu-
matology (OMERACT)–Osteoarthritis Research Society Interna-
tional (OARSI) “strict” criteria (defined as ≥50% improvement
and an absolute improvement of ≥20 points from baseline in
either ADP intensity or the WOMAC physical function subscale)
(10) at weeks 4, 8, 12, 16, 20, and 24; change from baseline to
each week (except weeks 12, 16, 20, and 24 as outlined above,
which are specified as the primary and secondary end points) in
weekly mean ADP intensity score; change from baseline to each
of weeks 4, 8, 12, 16, 20, and 24 in the WOMAC pain subscale;
change from baseline to each of weeks 4, 8, 16, 20, and 24 in the
WOMAC physical function subscale and PGIC; and time to onset
of pain relief (time to first ADP intensity assessment showing
>30% improvement from baseline).
To quantify the magnitude of difference between
FX006 16 mg and 32 mg and saline placebo, standardized
effect sizes were determined post hoc using methods
described previously (11) (see the Supplementary text, avail-
able on the Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.40364/abstract). Safety sum-
maries included treated patients.
This trial was conducted according to Good Clinical
Practice guidelines. Each site’s governing ethics body approved
the protocol, and participants provided written informed consent.
RESULTS
Patient disposition and baseline characteristics.
The trial was conducted from April 29, 2014 to August
8, 2015. Participants were screened at 48 sites (43 in
the US and 5 in Canada) and enrolled at 44 sites (40
in the US and 4 in Canada). Among 310 randomized
participants, 306 were treated (4 randomized to saline
placebo were not treated). Approximately 8% and 18%
of participants prematurely discontinued participation
through week 12 (primary end point) and week 24
(study completion), respectively (Figure 1). Ultrasound
guidance during IA injection was used in 4 patients.
All baseline characteristics, except sex, were gener-
ally well-balanced across arms. A higher proportion of
men comprised the FX006 32 mg group (51%) compared
with the 16 mg group (39%) or saline placebo group
(39%). Baseline ADP intensity scores (mean 6.6) indicated
substantial daily pain at a moderate level of intensity
(Table 1).
Efficacy. The primary end point was not met. The
least squares mean (LSM) change in ADP intensity at
week 12 was 3.1 with FX006 32 mg versus 2.5 with sal-
ine placebo. The LSM difference in ADP intensity (95%
confidence interval [95% CI]) for FX006 32 mg versus
saline placebo at week 12 was 0.58 (1.22, 0.07) (P =
0.08). However, FX006 32 mg resulted in significant
improvements in ADP intensity versus saline placebo at
each of weeks 1–11 (P ≤ 0.036) and week 13 (P ≤ 0.039)
and numerical improvements at week 12 and each of
weeks 14–24 (Figure 2A). Patients receiving FX006 16 mg
had significant improvements in ADP at weeks 1–9; there-
after, the difference in pain scores between FX006 16 mg
and saline placebo was small and not statistically signifi-
cant (Figure 2A). As such, a dose-response effect was evi-
dent in the duration of maximal effect. FX006 16 mg and
32 mg had similar median time to onset of analgesic effect
(day 4), which was more rapid than saline placebo (day 8).
The maximum magnitude of analgesic effect was similar
for FX006 16 mg and 32 mg (achieved at weeks 4–5; LSM
difference 1.22 for FX006 16 mg at week 4, 1.23 for
FX006 16 mg at week 5, 1.36 for FX006 32 mg at week
4, and 1.34 for FX006 32 mg at week 5) (Figure 2A).
Sensitivity analyses of the primary end point (last
observation carried forward [LOCF]/baseline observation
carried forward [BLOCF]) addressing patient discontinu-
ations prior to week 12 showed that ADP intensity was
significantly improved with FX006 32 mg versus saline
placebo at each visit from weeks 1 to 13 (all P < 0.05),
including week 12 (LSM difference [95% CI] 0.67
[1.32, 0.02]; P = 0.042) (Figure 2B). Results of a multi-
ple imputation sensitivity analysis of the primary end
point demonstrated consistent differences between
FX006 32 mg and saline placebo in ADP intensity
changes from baseline to week 12 (LSM difference [95%
CI] 0.65 [1.30, 0.01]; P = 0.053) (data not shown).
Consistent results were observed from a post hoc explor-
atory primary end point analysis performed with site
added to the MMRM as a covariate (week 12 LSM differ-
ence [95% CI] 0.72 [1.39, 0.05]; P = 0.034) (data not
shown). Inclusion of the 4 patients who were randomized
and not treated (i.e., the intent-to-treat population)
yielded results identical to those of the analysis based on
the full analysis set population, because none of these 4
patients had efficacy data after their screening visit.
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Results from secondary analyses also favored
FX006 32 mg compared with saline placebo. FX006 32
mg was associated with significantly improved WOMAC
pain (Figure 2C), WOMAC physical function (Fig-
ure 2D), and PGIC (Figure 2E) scores, and resulted in a
higher proportion of patients who achieved OMERACT-
OARSI “strict” responder criteria versus saline placebo at
week 4 and week 8 (Supplementary Table 1, available on
the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40364/abstract). Numerical ad-
vantage was maintained at week 12 for all of these end
points except OMERACT-OARSI “strict” responders.
Secondary end point findings for FX006 16 mg versus sa-
line placebo showed a similar pattern, with a reduced
duration of effect, no trend favoring FX006 16 mg over
saline placebo for improvements in ADP intensity at week
12, and lower OMERACT-OARSI “strict” response rates
at week 8 (Figure 2A and Supplementary Table 1).
Results from post hoc standardized effect size deter-
minations indicated that the effect sizes based on ADP
were consistently lower than those for the WOMAC pain
subscale. The ADP effect sizes for FX006 32 mg at weeks
4, 8, and 12 were 0.27, 0.13, and 0.12, respectively, and the
effect sizes for the WOMAC pain subscale were 0.72, 0.54,
and 0.27, respectively. For each instrument, the effect sizes
for FX006 16 mg were similar to those of FX006 32 mg at
weeks 4 and 8. Consistent with prespecified secondary end
points, effect sizes for both ADP and the WOMAC pain
subscale were markedly lower for FX006 16 mg versus
FX006 32 mg at week 12 (Supplementary Table 2, available
on the Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.40364/abstract).
Safety. Similar proportions of participants reported
AEs through week 24 across treatment arms (Table 2).
Most AEs were grade 1 or 2, nonserious, and considered
unrelated to the study drug by investigators who were
blinded with regard to treatment group. No deaths
occurred. Serious AEs occurred in 4 (1.9%) of the FX006-
treated patients (left distal femur fracture in the 16 mg
group and worsening left ankle OA, myocardial infarction,
and rheumatoid arthritis in the 32 mg group). All were
unrelated to study drug. No AE was consistent with postin-
jection flare. AEs causing study discontinuation occurred
in 8 (3.9%) of the FX006-treated patients and 1 (1.0%) of
the saline placebo–treated patients (Table 2). The onset of
such events was not temporally associated with study drug
administration. All of these events were considered unre-
lated to study drug except for 1 grade 2 AE (in the FX006
16 mg group) and 1 grade 3 AE (in the saline placebo
group). The incidence of index knee–related AEs was rela-
tively low given the study population. AEs related to the
injection procedure were observed in 2.0%, 0%, and 6.0%
of FX006 16 mg–, FX006 32 mg–, and saline placebo–trea-
ted patients, respectively.
DISCUSSION
The primary end point of this study, significant
improvement in ADP intensity at week 12 with FX006 32
mg versus placebo, was not achieved (P = 0.08); however,
significant improvement with FX006 32 mg was seen at all
time points from week 1 to week 11 (P ≤ 0.036) and at
week 13 (P = 0.039). The placebo response at week 12
(LSM reduction of 2.5) was the largest reported over
the 24-week study. Studies show that placebo effects may
confound the interpretation of clinical data (12) and are
more pronounced with IA versus other routes of adminis-
tration (13). Differences in saline placebo response across
study sites were noted; a post hoc exploratory analysis
with a site covariate included in the MMRM accounted
for the variability in site responses, and the model demon-
strated statistical significance for the primary end point at
week 12 (P = 0.034). Sensitivity analyses (LOCF/BLOCF)
that addressed patient discontinuations prior to week 12
indicated that FX006 32 mg was significantly superior to
saline placebo at weeks 1–13 (P ≤ 0.042). Results of a
multiple imputation analysis demonstrated consistent dif-
ferences between FX006 32 mg and saline placebo in
ADP intensity changes from baseline to week 12.
Although FX006 16 mg and 32 mg had compara-
ble median times to onset of analgesia (day 4) and pro-
vided similar and significant maximal analgesic effects
(beginning at approximately week 5) versus saline pla-
cebo, maximal effect persisted longer with FX006 32 mg
(to approximately week 13) than 16 mg (to approxi-
mately week 9). Numerically larger pain relief, as mea-
sured by ADP intensity, was maintained with FX006 32
mg versus saline placebo at all time points through week
24. Other measures of OA signs/symptoms (WOMAC
physical function subscale, PGIC, WOMAC pain sub-
scale, and OMERACT-OARSI “strict” response) were
significantly improved with FX006 32 mg through week 8
with strong trends remaining at week 12; results for
FX006 16 mg versus saline placebo showed a similar pat-
tern but were not as robust or long lasting. A previous
clinical study of FX006 in patients with OA demon-
strated a dose-dependent increase in synovial fluid con-
centrations of triamcinolone acetonide at week 6
following IA injection (14). It is postulated that there is a
critical synovial fluid concentration required to maintain
an analgesic effect and that the loss of analgesic effect
after week 9 with FX006 16 mg is attributable to synovial
fluid triamcinolone acetonide levels dropping below that
critical concentration.
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The clinical relevance of these findings was assessed
with post hoc analysis of standardized effect size (11), a
measure used to quantify the magnitude of difference
between 2 treatment groups. An effect size >0.3 is consid-
ered an important change for a patient-reported outcome
(15). For FX006 32 mg compared with saline placebo,
effect size for the WOMAC pain instrument exceeded 0.30
at weeks 4 and 8 and approached 0.30 at week 12. Effect
size with the 16-mg dose was comparable to that of the
32-mg dose at week 4 but was notably lower at week 8, and
no active treatment effect was seen at week 12. Effect sizes
assessed with ADP were consistently lower than those for
the WOMAC pain subscale for both FX006 doses at each
of these time points. Across a large number of trials, the
multi-item, knee OA–specific WOMAC pain instrument
has proved to be a more sensitive measure of treatment
effect than the single-item, general purpose ADP intensity
0–10 NRS (11). Overall, both FX006 doses demonstrated
systemic and local safety profiles similar to saline placebo.
No FX006 dose relationship in AEs was apparent.
In conclusion, although the study’s primary end
point was not met, the dose effect on duration of anal-
gesic efficacy observed in this phase IIb study of people
with knee OA confirms that FX006 32 mg confers in-
creased therapeutic benefit relative to FX006 16 mg with
similar safety, and that improvements in pain afforded by
FX006 32 mg were of a magnitude that would be impor-
tant to patients.
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